By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Synageva BioPharma 

Corporate Offices
128 Spring Street, Suite 520
Lexington  Massachusetts  02421  U.S.A.
Phone: 781-890-1111 Fax: 781-890-1114


SEARCH JOBS

Synageva BioPharma is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and unmet medical need. Our lead program, SBC-102, an enzyme replacement therapy for LAL Deficiency, is currently being evaluated in global Phase I/II clinical trials. SBC-102 has been granted orphan designations by the U.S. Food and Drug Administration (“FDA”) and the European Medicines Agency and fast track designation by the FDA. Synageva has several protein therapeutics focused on life threatening conditions in its pipeline. The Company has assembled a team with a proven record of bringing orphan therapies to patients.


Key Statistics


Email: info@synageva.com
Ownership: Public

Web Site: Synageva BioPharma
Employees:
Symbol: GEVA
 









Company News
Synageva BioPharma (GEVA) Submits Kanuma (Sebelipase Alfa) Application For LAL Deficiency In Mexico 3/30/2015 11:58:02 AM
1,075 New Jobs to be Added by 11 Life Science Firms in Massachusetts: Amgen (AMGN), Alnylam (ALNY), Biogen Idec, Inc. (North Carolina) (BIIB), GE Healthcare Bio-Sciences, Quest Diagnostics (DGX), Alkermes (ALKS), Baxter Healthcare (BAX), Merrimack (MACK), Synageva BioPharma (GEVA), Philips Electronics, SMC 3/19/2015 6:51:59 AM
Synageva BioPharma (GEVA) Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2/27/2015 10:29:19 AM
Synageva BioPharma (GEVA) Reports 2014 Full Year Financial Results 2/27/2015 7:20:13 AM
Synageva BioPharma (GEVA) To Present At The Cowen and Company Health Care Conference 2/25/2015 10:28:22 AM
FDA Accepts BLA Filing For Synageva BioPharma (GEVA)'s Kanuma (Sebelipase Alfa); Grants Priority Review And Assigns Pdufa Date 2/23/2015 6:41:04 AM
Synageva BioPharma (GEVA) To Host 2014 Fourth Quarter And Full Year Financial Results Conference Call On February 26 2/19/2015 11:51:18 AM
Synageva BioPharma (GEVA) European Patent Issued For Treatment Of LAL Deficiency 2/18/2015 10:51:09 AM
Synageva BioPharma (GEVA) Announces Presentations At 11th Annual World Symposium 2/11/2015 11:11:38 AM
Synageva BioPharma (GEVA) Announces Dosing Of Patients Commenced With SBC-103 In Phase 1/2 Study For Mucopolysaccharidosis IIIB And FDA Fast Track Designation Granted 1/26/2015 7:31:32 AM
12345678910...
//-->